AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34383157 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence to public health safety behaviors
Number of subjects: 20000
Study 34383274 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous trigeminal electrical neuromodulation (TTEN)
Number of subjects: 13
Study 34383289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous onasemnogene abeparvovec
Number of subjects: 102
Study 34383370 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (150 mg/m² continuous oral twice daily) with Irinotecan (oral, once daily days 1-5, every 21 days)
Number of subjects: 15
Study 34383370 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (150 mg/m²)
Number of subjects: 15
Study 34383393 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy
Number of subjects: 0
Study 34383569 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34383662 — intervention group
Group type: EXPERIMENTAL
Intervention: VR simultaneous motor-cognitive training (cognitive games and cycling on an ergometer simultaneously on a VR platform)
Number of subjects: 17
Study 34383662 — intervention group
Group type: COMPARATOR
Intervention: Control group (cognitive games on tablet computers and cycling on the ergometer sequentially on a non-VR platform)
Number of subjects: 17
Study 34383662 — intervention group
Group type: EXPERIMENTAL
Intervention: VR simultaneous motor-cognitive training
Number of subjects: 17
Study 34383675 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared review process of electronic patient-reported outcomes (ePRO)
Number of subjects: 181
Study 34383676 — intervention group
Group type: EXPERIMENTAL
Intervention: Bizi Orain, a 3-month supervised exercise program (3 times a week) with behavioral counseling in a primary health care setting.
Number of subjects: 265
Study 34383676 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (control group).
Number of subjects: 265
Study 34383676 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (prospective study).
Number of subjects: 265
Study 34383681 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) treatment
Number of subjects: 133
Study 34383681 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 133
Study 34383682 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable devices (Garmin vivofit for activity monitoring, Philips Actiwatch for sleep monitoring) and smartphones for patient-reported outcomes.
Number of subjects: 40
Study 34383682 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly patient-reported outcomes using Brief Psychiatric Rating Scale, Calgary Depression Scale, and Positive and Negative Syndrome Scale.
Number of subjects: 40
Study 34383682 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic net model using sleep and activity features from wearable devices.
Number of subjects: 40
Study 34383682 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall data coverage and compliance with devices.
Number of subjects: 40
Study 34383774 — intervention group
Group type: EXPERIMENTAL
Intervention: STANDARD G6PD Test (SD Biosensor)
Number of subjects: 1736
Study 34383875 — intervention group
Group type: EXPERIMENTAL
Intervention: Device ON
Number of subjects: 4
Study 34383875 — intervention group
Group type: COMPARATOR
Intervention: Device OFF
Number of subjects: 4
Study 34383902 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous ChAdOx1-S/BNT162b2 Vaccination
Number of subjects: 0
Study 34384049 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive services (exercise classes) in retirement communities
Number of subjects: 23
Study 34384049 — intervention group
Group type: COMPARATOR
Intervention: No supportive services (exercise classes) in retirement communities
Number of subjects: 23
Study 34384079 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 consecutive intracavernous injections of allogeneic Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs)
Number of subjects: 22
Study 34384145 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1958
Study 34384227 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Treatment Study of ADHD (MTA)
Number of subjects: 558
Study 34384384 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized neurological examination
Number of subjects: 0
Study 34384384 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held dynamometry (age ≥ 5 years)
Number of subjects: 0
Study 34384384 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional measurements
Number of subjects: 0
Study 34384384 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires (patient report and/or parent proxy; age ≥ 2 years)
Number of subjects: 0
Study 34384384 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle ultrasound including diaphragm
Number of subjects: 0
Study 34384384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (spirometry, maximal inspiratory and expiratory pressure, sniff nasal inspiratory pressure; age ≥ 5 years)
Number of subjects: 0
Study 34384384 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry for 8 days (age ≥ 2 years)
Number of subjects: 0
Study 34384384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac evaluation (electrocardiogram, echocardiography; age ≥ 2 years)
Number of subjects: 0
Study 34384384 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine X-ray (age ≥ 2 years)
Number of subjects: 0
Study 34384384 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DEXA-scan; age ≥ 2 years)
Number of subjects: 0
Study 34384384 — intervention group
Group type: EXPERIMENTAL
Intervention: Full body magnetic resonance imaging (MRI; age ≥ 10 years)
Number of subjects: 0
Study 34384460 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated suPAR above 3 ng/ml
Number of subjects: 414
Study 34384460 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated suPAR above 9 ng/ml
Number of subjects: 414
Study 34384460 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate
Number of subjects: 414
Study 34384490 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline procedures including neurological and neuropsychological examinations; tau and amyloid positron emission tomography; magnetic resonance imaging and spectroscopy; lumbar puncture; blood and saliva collection; standardized self-report measures of neuropsychiatric, cognitive, and daily functioning.
Number of subjects: 240
Study 34384490 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote, 4-year follow-up evaluations including telephone-, online-, and videoconference-based cognitive, neuropsychiatric, and neurologic examinations, as well as in-home blood draw.
Number of subjects: 240
Study 34384695 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiotherapy (SABR) 28.5 Gy in 3 fractions
Number of subjects: 19
Study 34384695 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI %VR
Number of subjects: 19
Study 34384709 — intervention group
Group type: EXPERIMENTAL
Intervention: MS4A family members as candidate biomarkers and therapeutic targets
Number of subjects: 0
Study 34384766 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional clusters
Number of subjects: 1967
Study 34384766 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease clusters
Number of subjects: 1967
Study 34384766 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson score
Number of subjects: 1967
Study 34384766 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity
Number of subjects: 1967
Study 34385099 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD screening intervention involving questionnaires, spirometry (COPD6™), and counselling
Number of subjects: 157
Study 34385099 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling including smoking cessation and chest physician referral
Number of subjects: 157
Study 34385099 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling including smoking cessation
Number of subjects: 157
Study 34385234 — intervention group
Group type: EXPERIMENTAL
Intervention: Extubation Advisor (EA) clinical decision support tool
Number of subjects: 117
Study 34385256 — intervention group
Group type: EXPERIMENTAL
Intervention: Active commuting (walking or cycling)
Number of subjects: 2815
Study 34385256 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or vigorous leisure-time physical activity (LTPA)
Number of subjects: 2815
Study 34385256 — intervention group
Group type: EXPERIMENTAL
Intervention: Active commuting among different employment statuses
Number of subjects: 2815
Study 34385256 — intervention group
Group type: EXPERIMENTAL
Intervention: Active commuting and weight status
Number of subjects: 2815
Study 34385256 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (LTPA) and age
Number of subjects: 2815
Study 34385256 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (LTPA) and gender
Number of subjects: 2815
Study 34385263 — intervention group
Group type: EXPERIMENTAL
Intervention: Single blood eosinophil count measurement
Number of subjects: 0
Study 34385263 — intervention group
Group type: COMPARATOR
Intervention: Two blood eosinophil count measurements
Number of subjects: 0
Study 34385343 — intervention group
Group type: EXPERIMENTAL
Intervention: DARPin G3 (designed ankyrin repeat proteins)
Number of subjects: 0
Study 34385584 — intervention group
Group type: EXPERIMENTAL
Intervention: ZEN-3694 combined with CDK4/6 inhibitors
Number of subjects: 0
Study 34385584 — intervention group
Group type: EXPERIMENTAL
Intervention: ZEN-3694 treatment
Number of subjects: 0
Study 34385593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 16
Study 34385708 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocytes (TILs) administered with nivolumab
Number of subjects: 20
Study 34385708 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety endpoint
Number of subjects: 20
Study 34385708 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL treatment
Number of subjects: 20
Study 34385840 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) angioplasty
Number of subjects: 200
Study 34385840 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 200
Study 34385840 — intervention group
Group type: COMPARATOR
Intervention: Both DCB angioplasty and PTA
Number of subjects: 200
Study 34385972 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34386129 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 0
Study 34386129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy defibrillator (CRT-D)
Number of subjects: 0
Study 34386129 — intervention group
Group type: COMPARATOR
Intervention: Nondevice (ND)
Number of subjects: 0
Study 34386129 — intervention group
Group type: COMPARATOR
Intervention: HF pacing (PA; Pacemaker and cardiac resynchronization pacemaker)
Number of subjects: 0
Study 34386535 — intervention group
Group type: EXPERIMENTAL
Intervention: BESMILE-HF Program
Number of subjects: 0
Study 34386535 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34386974 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 10039
Study 34386974 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombopoietin-receptor agonists (TPO-RAs)
Number of subjects: 10039
Study 34386974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 10039
Study 34386974 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 10039
Study 34386974 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 10039
Study 34386974 — intervention group
Group type: EXPERIMENTAL
Intervention: History of VT
Number of subjects: 10039
Study 34386974 — intervention group
Group type: EXPERIMENTAL
Intervention: History of cancer
Number of subjects: 10039
Study 34386974 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 10039
Study 34386974 — intervention group
Group type: EXPERIMENTAL
Intervention: History of cardiovascular disease
Number of subjects: 10039
Study 34386974 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 10039
Study 34387097 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 1680
Study 34387097 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 1680
Study 34387097 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with low flow (LF)
Number of subjects: 1680
Study 34387097 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVR with low flow (LF) and low ejection fraction
Number of subjects: 1680
Study 34387097 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal flow
Number of subjects: 1680
Study 34387119 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) therapy, 2 times a week for 6 weeks (total of 12 treatments)
Number of subjects: 12
Study 34387310 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 polymerase chain reaction, immunoglobulin G (IgG) testing for 6 months
Number of subjects: 831
Study 34387310 — intervention group
Group type: COMPARATOR
Intervention: Healthcare workers (n = 548)
Number of subjects: 831
Study 34387310 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG antibodies detection
Number of subjects: 831
Study 34387310 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG trajectories
Number of subjects: 831
Study 34387310 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent IgG responses
Number of subjects: 831
Study 34387310 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom severity
Number of subjects: 831
Study 34387310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea and neurologic changes
Number of subjects: 831
Study 34387310 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged symptoms
Number of subjects: 831
Study 34387570 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (bedside irrigation, primary closure, antibiotics, discharge with follow-up)
Number of subjects: 189
Study 34387570 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (surgical debridement, irrigation, and closure)
Number of subjects: 189
Study 34387570 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 189
Study 34387648 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine (2 doses, 21 days apart)
Number of subjects: 149
Study 34387648 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 149
Study 34387648 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine (in patients with B-NHL)
Number of subjects: 149
Study 34387648 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine (in patients with i-B-NHL vs a-B-NHL)
Number of subjects: 149
Study 34387673 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic venous insufficiency (CVI)
Number of subjects: 12423
Study 34387673 — intervention group
Group type: EXPERIMENTAL
Intervention: CVI
Number of subjects: 12423
Study 34387679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol, 300 mg (150 mg twice per day) plus standard care
Number of subjects: 120
Study 34387679 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 120
Study 34387718 — intervention group
Group type: EXPERIMENTAL
Intervention: Patlak analysis
Number of subjects: 8
Study 34388020 — intervention group
Group type: EXPERIMENTAL
Intervention: VenDd (venetoclax with daratumumab and dexamethasone)
Number of subjects: 48
Study 34388020 — intervention group
Group type: EXPERIMENTAL
Intervention: VenDVd (venetoclax with daratumumab, dexamethasone, and bortezomib)
Number of subjects: 48
Study 34388205 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiated immediately after diagnosis of acute HIV infection.
Number of subjects: 22
Study 34388205 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the state without ART).
Number of subjects: 22
Study 34388324 — intervention group
Group type: EXPERIMENTAL
Intervention: HE4
Number of subjects: 445
Study 34388324 — intervention group
Group type: EXPERIMENTAL
Intervention: CA125
Number of subjects: 445
Study 34388386 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg per day; or 0.75 mg per day in patients with moderate renal impairment)
Number of subjects: 128
Study 34388972 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) ß-1a, 3 doses of 125 μg by subcutaneous administration (days 1, 6, and 11)
Number of subjects: 310
Study 34388972 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 310
Study 34388972 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) ß-1a
Number of subjects: 310
Study 34389003 — intervention group
Group type: COMPARATOR
Intervention: Nesfatin-1 levels in CAD groups (UA & SCAD)
Number of subjects: 240
Study 34389003 — intervention group
Group type: COMPARATOR
Intervention: DPP4 levels in CAD groups (UA & SCAD)
Number of subjects: 240
Study 34389003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesfatin-1 correlation with hsCRP
Number of subjects: 240
Study 34389003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesfatin-1 correlation with HOMA-IR
Number of subjects: 240
Study 34389003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesfatin-1 correlation with hyperlipidemia
Number of subjects: 240
Study 34389003 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP4 correlation with hs-CRP
Number of subjects: 240
Study 34389003 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP4 correlation with FPG
Number of subjects: 240
Study 34389003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesfatin-1 correlation with severity of CAD (Gensini score)
Number of subjects: 240
Study 34389003 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP4 association with severity of CAD
Number of subjects: 240
Study 34389009 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless ultrasound-guided central venous catheter insertion (CVC)
Number of subjects: 30
Study 34389161 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment strategies attempted over the years for G6PD deficiency
Number of subjects: 400000000
Study 34389161 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential pharmacological pathways including glutathione (GSH) metabolism and compensatory NADPH production routes
Number of subjects: 400000000
Study 34389161 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptional upregulation of the G6PD gene
Number of subjects: 400000000
Study 34389234 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4300
Study 34389234 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 4300
Study 34389237 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel osimertinib combination therapies (Group A)
Number of subjects: 0
Study 34389237 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-biomarker selected therapies (chemotherapy- or EGFR-TKI-based) (Group B)
Number of subjects: 0
Study 34389237 — intervention group
Group type: COMPARATOR
Intervention: Local practice treatment (Group C)
Number of subjects: 0
Study 34389237 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study endpoints
Number of subjects: 0
Study 34389504 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy for peanut allergy
Number of subjects: 0
Study 34389568 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic bariatric surgery (MBS), specifically vertical sleeve gastrectomy (VSG), details on dosage and duration not available.
Number of subjects: 0
Study 34389568 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment approaches including lifestyle change, metformin, thiazolidinediones, or insulin, details on dosage and duration not available.
Number of subjects: 0
Study 34389610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular plasmid treatment
Number of subjects: 0
Study 34389610 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of plasmid
Number of subjects: 0
Study 34389610 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified plasmid (for first-in-human studies)
Number of subjects: 0
Study 34389618 — intervention group
Group type: EXPERIMENTAL
Intervention: GWN323 (1500 mg every 3 weeks)
Number of subjects: 92
Study 34389618 — intervention group
Group type: EXPERIMENTAL
Intervention: GWN323 (750 mg) + spartalizumab (300 mg every 3 weeks)
Number of subjects: 92
Study 34389618 — intervention group
Group type: COMPARATOR
Intervention: GWN323 (single-agent)
Number of subjects: 92
Study 34389618 — intervention group
Group type: COMPARATOR
Intervention: GWN323 + spartalizumab (combination)
Number of subjects: 92
Study 34389656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in smokers
Number of subjects: 0
Study 34389656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in ex-smokers
Number of subjects: 0
Study 34389656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in never-smokers
Number of subjects: 0
Study 34389694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolinapant (ASTX660)
Number of subjects: 0
Study 34389694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolinapant (ASTX660) + FOLFOX
Number of subjects: 0
Study 34389694 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5FU)-based adjuvant chemotherapy
Number of subjects: 0
Study 34389923 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally grounded physical activity intervention (hula lessons and self-regulation classes) for 12 months
Number of subjects: 263
Study 34389923 — intervention group
Group type: COMPARATOR
Intervention: Education-only waitlist control group
Number of subjects: 263
Study 34389923 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally grounded physical activity intervention
Number of subjects: 263
Study 34389930 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pumps
Number of subjects: 2623
Study 34389930 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 2623
Study 34389930 — intervention group
Group type: COMPARATOR
Intervention: Multiple Daily Injections (MDI)
Number of subjects: 2623